9969.HK Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 Apr 2024 @ 09:59):

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases...

Stats
Tagesvolumen	2.91M
Durchschnittsvolumen	3.52M
Marktkapitalisierung	6.76B
EPS	HKD0 ( 2022-03-22 )
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-11.27
ATR14	HKD0.00500 (0.11%)

Volumen Korrelation

Lang: 0.03 (neutral)

Kurz: -0.92 (very strong negative)

Signal:(35.008) Neutral

InnoCare Pharma Ltd Korrelation

10 Am meisten positiv korreliert

10 Am meisten negativ korreliert

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

InnoCare Pharma Ltd Korrelation - Währung/Rohstoff

-0.70
( moderate negative )

-0.59
( weak negative )

0.00
( neutral )

-0.60
( weak negative )

0.00
( neutral )

0.80
( moderate )

InnoCare Pharma Ltd Finanzdaten

Annual	2023
Umsatz:	HKD738.54M
Bruttogewinn:	HKD610.10M (82.61 %)
EPS:	HKD-0.370

FY	2023
Umsatz:	HKD738.54M
Bruttogewinn:	HKD610.10M (82.61 %)
EPS:	HKD-0.370

FY	2022
Umsatz:	HKD625.40M
Bruttogewinn:	HKD482.01M (77.07 %)
EPS:	HKD-0.590

FY	2021
Umsatz:	HKD1.04B
Bruttogewinn:	HKD977.37M (93.70 %)
EPS:	HKD-0.0500

Financial Reports:

No articles found.

InnoCare Pharma Ltd

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.